febuxostat has been researched along with sulfasalazine in 5 studies
| Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) | Studies (sulfasalazine) | Trials (sulfasalazine) | Recent Studies (post-2010) (sulfasalazine) |
|---|---|---|---|---|---|
| 818 | 133 | 710 | 4,437 | 585 | 938 |
| Protein | Taxonomy | febuxostat (IC50) | sulfasalazine (IC50) |
|---|---|---|---|
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 1.5 | |
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | 3 | |
| Carbonic anhydrase 1 | Homo sapiens (human) | 3.04 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 4.49 | |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 6.332 | |
| Sodium/bile acid cotransporter | Homo sapiens (human) | 9.6 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.46 | |
| Cystine/glutamate transporter | Homo sapiens (human) | 0.16 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.56 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chakrabarti, KS; Choi, J; de Groot, BL; Gapsys, V; Griesinger, C; Ha, JH; Jee, JG; Kim, BR; Kim, M; Lee, D; Lee, KO; Ryu, KS | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Abu-Risha, SE; Amer, MS; El-Mahdy, NA; Saleh, DA | 1 |
2 review(s) available for febuxostat and sulfasalazine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
3 other study(ies) available for febuxostat and sulfasalazine
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic Target.
Topics: Catalytic Domain; Crystallography, X-Ray; Drug Repositioning; Enzyme Inhibitors; Humans; Molecular Dynamics Simulation; Nuclear Magnetic Resonance, Biomolecular; Oxidoreductases Acting on CH-CH Group Donors; Protein Binding; Small Molecule Libraries; Thermodynamics; United States; United States Food and Drug Administration | 2022 |
Role of allopurinol and febuxostat in the amelioration of dextran-induced colitis in rats.
Topics: Allopurinol; Animals; Anti-Inflammatory Agents; Colitis, Ulcerative; Colon; Dextran Sulfate; Drug Therapy, Combination; Febuxostat; Glutathione; Interleukin-1beta; Interleukin-6; Male; Malondialdehyde; Rats, Wistar; Sulfasalazine; Superoxide Dismutase; Uric Acid; Xanthine Oxidase | 2020 |